Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
REGN

REGN - Regeneron Pharmaceuticals Inc Stock Price, Fair Value and News

1053.66USD+9.27 (+0.89%)Market Closed

Market Summary

REGN
USD1053.66+9.27
Market Closed
0.89%

REGN Alerts

  • 6 major insider sales recently.

REGN Stock Price

View Fullscreen

REGN RSI Chart

REGN Valuation

Market Cap

113.6B

Price/Earnings (Trailing)

29.44

Price/Sales (Trailing)

8.67

EV/EBITDA

24.83

Price/Free Cashflow

23.97

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

30.85%

Return on Equity

14.29%

Return on Assets

11.22%

Free Cashflow Yield

4.17%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

13.1B

Rev. Growth (Yr)

-0.54%

Rev. Growth (Qtr)

-8.42%

REGN Earnings

Earnings (TTM)

3.9B

Earnings Growth (Yr)

-11.71%

Earnings Growth (Qtr)

-37.74%

Breaking Down REGN Revenue

Last 7 days

1.7%

Last 30 days

7.1%

Last 90 days

8.9%

Trailing 12 Months

35.1%

How does REGN drawdown profile look like?

REGN Financial Health

Current Ratio

5.27

Debt/Equity

0.07

Debt/Cashflow

2.39

REGN Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

33.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202413.1B000
202312.4B12.7B13.1B13.1B
202216.5B14.2B13.5B12.2B
20219.2B12.4B13.5B16.1B
20207.0B7.4B7.9B8.5B
20196.6B6.5B6.6B6.6B
20186.1B6.2B6.4B6.7B
20175.0B5.2B5.5B5.9B
20164.4B4.6B4.7B4.9B
20153.1B3.4B3.8B4.1B
20142.3B2.5B2.6B2.8B
20131.6B1.7B1.9B2.1B
2012565.4M762.0M1.1B1.4B
2011467.7M459.7M456.5M445.8M
2010407.8M433.7M422.2M459.1M
20090285.4M332.3M379.3M
2008000238.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Regeneron Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
brown michael s
sold
-1,596,400
1,040
-1,535
-
Jun 14, 2024
brown michael s
acquired
960,296
625
1,535
-
Jun 12, 2024
schleifer leonard s
sold
-1,025,270
1,025
-1,000
bd. co-chair, president & ceo
Jun 12, 2024
schleifer leonard s
acquired
-
-
1,000
bd. co-chair, president & ceo
Jun 12, 2024
schleifer leonard s
sold
-15,381,100
1,015
-15,149
bd. co-chair, president & ceo
Jun 11, 2024
schleifer leonard s
sold
-9,203,820
1,015
-9,064
bd. co-chair, president & ceo
Jun 10, 2024
yancopoulos george
gifted
-
-
37,900
bd. co-chair, president & cso
Jun 10, 2024
larosa joseph j
gifted
-
-
-1,608
evp general counsel and secret
Jun 10, 2024
yancopoulos george
gifted
-
-
-75,799
bd. co-chair, president & cso
Jun 06, 2024
schleifer leonard s
sold
-798,821
1,015
-787
bd. co-chair, president & ceo

1–10 of 50

Which funds bought or sold REGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 21, 2024
Abich Financial Wealth Management LLC
sold off
-100
-7,026
-
-%
Jun 20, 2024
HM PAYSON & CO
sold off
-100
-13,175
-
-%
Jun 13, 2024
KEYNOTE FINANCIAL SERVICES LLC
new
-
481,245
481,245
0.40%
Jun 13, 2024
IMS Capital Management
sold off
-100
-245,921
-
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-1.71
-1,521
459,581
0.04%
Jun 10, 2024
Hamilton Wealth, LLC
added
72.01
208,326
443,708
0.14%
Jun 07, 2024
Railway Pension Investments Ltd
added
1.44
2,717,340
27,046,000
0.26%
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
reduced
-2.08
819,000
12,034,000
0.09%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-1.34
16,365,000
212,634,000
0.40%
May 30, 2024
CAMBRIDGE TRUST CO
reduced
-93.63
-128,267
9,625
-%

1–10 of 48

Are Funds Buying or Selling REGN?

Are funds buying REGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own REGN
No. of Funds

Unveiling Regeneron Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.25%
8,838,240
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital world investors
4.8%
5,194,729
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
6.7%
7,219,436
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
6.7%
7,219,436
SC 13G/A
Jan 25, 2024
blackrock inc.
8.1%
8,629,707
SC 13G/A
Feb 13, 2023
capital world investors
5.9%
6,315,819
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.15%
8,722,448
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
9,166,817
SC 13G/A

Recent SEC filings of Regeneron Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 20, 2024
8-K
Current Report
Jun 17, 2024
4
Insider Trading
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 13, 2024
4
Insider Trading
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Regeneron Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Regeneron Pharmaceuticals Inc News

Latest updates
Defense World36 hours ago

Regeneron Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-8.4%3,1453,4343,3633,1583,1623,4142,9362,8972,8572,9654,9523,4535,1392,5292,4232,2941,9521,8281,8641,7441,578
Costs and Expenses-2.8%2,3942,4612,2522,1422,2152,2681,713-1,7471,7072,3121,6061,7911,4161,2561,2411,2961,1281,1881,0051,262
  S&GA Expenses-6.6%689738641652601661529-476450560445415406304327348367452304295
  R&D Expenses6.0%1,2481,1771,0751,0851,1011,043911-794844738665714743657685722584552526886
EBITDA Margin-3.0%0.35*0.36*0.37*0.41*0.41*0.43*0.50*0.49*0.47*0.57*0.60*0.62*0.61*0.51*0.48*0.47*0.47*0.40*0.41*0.37*0.35*
Interest Expenses-12.0%16.0018.0018.0019.0018.0017.0015.00-13.0014.0014.0014.0014.0015.0015.0026.0010.006.007.008.008.00
Income Taxes-77.5%-21.30-12.0010311540.00128194-11188.0027418465413875.0015622.0044.0098.0099.0032.00
Earnings Before Taxes-38.9%7011,1481,1111,0838581,3251,510-9631,0612,5031,8173,7531,2531,225998919669890769225
EBT Margin-3.6%0.31*0.32*0.33*0.38*0.37*0.40*0.47*0.47*0.45*0.55*0.58*0.59*0.58*0.48*0.45*0.44*0.44*0.36*0.37*0.33*0.32*
Net Income-37.7%7221,1601,0089688181,1971,316-8529742,2291,6323,0991,1151,149842897625792670193
Net Income Margin-2.3%0.29*0.30*0.30*0.34*0.34*0.36*0.42*0.42*0.40*0.48*0.50*0.52*0.50*0.44*0.41*0.40*0.40*0.33*0.32*0.32*0.32*
Free Cashflow38.8%1,5131,0901,1141,0221,3681,7206295645642,1022,3733,4146276691,231-254943698787557188
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets3.9%34,37033,08032,16330,65830,06029,21527,67827,20626,34925,43523,67221,48617,77217,16316,08414,42915,75814,80513,93913,17412,855
  Current Assets-3.1%18,87219,47918,63516,92316,90915,88415,42915,53014,30614,01513,77513,33810,0559,7799,0987,8608,6447,6897,1096,6516,929
    Cash Equivalents-4.7%2,6022,7302,1521,9373,9163,1193,4913,3953,3462,8863,4322,0721,4382,2071,5731,9922,2081,6301,3851,0461,709
  Inventory5.2%2,7152,5812,5622,5082,4252,4022,4122,2191,9921,9512,0541,9842,1651,9171,8021,6411,4811,4161,3441,3171,209
  Net PPE-------3,7043,6383,5563,4823,3963,3593,2633,2223,1383,0312,9452,8902,7712,6772,613
Liabilities3.8%7,3797,1077,2596,6406,5656,5516,2396,5186,4346,6666,4146,3595,7956,1385,9595,3713,6253,7163,4353,4183,410
  Current Liabilities4.6%3,5813,4233,5993,1043,1003,1412,8793,0343,0083,9333,7153,7323,2182,6972,3383,7022,0552,0971,7651,7131,511
  Long Term Debt0.0%1,9831,9831,9831,9821,9821,9811,9811,9811,9801,9801,9801,9791,9791,9791,978------
    LT Debt, Non Current0.0%1,9831,9831,9831,9821,9821,9811,9811,9811,9801,9801,9801,9791,9791,9791,978------
Shareholder's Equity3.9%26,99125,97324,90424,01823,49522,66421,43920,68819,91518,76917,25815,12711,97711,02510,1269,05712,13311,09010,5049,7569,445
  Retained Earnings2.6%27,98227,26026,10125,09324,12523,30722,11020,79419,94218,96816,73915,10712,00810,8939,7448,9028,0047,3806,5885,9185,725
  Additional Paid-In Capital5.2%11,94311,35411,25210,88910,5989,9499,5189,1208,7548,0887,9197,2266,8886,7166,5936,2635,2114,4294,3884,2644,161
Shares Outstanding1.0%108107107107107107107107107106106105105108106110110109109109109
Float----76,700---62,000---57,065---63,344---32,929-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations38.8%1,5131,0901,1141,0221,3681,7206295642,1022,3733,4146276691,231-254943698787557188897
  Share Based Compensation-4.3%230240204202239232166160167188137146131122101104106134117106108
Cashflow From Investing-2448.5%-1,687-66.20-496-2,386-235-1,857192-413-1,705-2,012-2,438126-1,059-305-7751,453-443-208-207-836-776
Cashflow From Financing110.6%47.00-446-407-614-322-247-725-10165.00-906385-118-366-305612-2,612336-345-11.00-15.30120
  Buy Backs-0.1%2912925077237114289133943528551912893243601005,07233624719.00-10.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

REGN Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenues$ 3,145.0$ 3,162.1
Expenses:  
Research and development1,248.41,101.2
Acquired in-process research and development7.156.1
Selling, general, and administrative689.0601.1
Other operating expense (income), net15.3(0.5)
Total Expenses2,393.62,215.4
Income from operations751.4946.7
Other income (expense):  
Other (expense) income, net(34.6)(70.7)
Interest expense(16.1)(18.0)
Total other income (expense)(50.7)(88.7)
Income before income taxes700.7858.0
Income tax (benefit) expense(21.3)40.2
Net income$ 722.0$ 817.8
Net income per share - basic (in dollars per share)$ 6.70$ 7.64
Net income per share - diluted (in dollars per share)$ 6.27$ 7.17
Weighted average shares outstanding - basic (in shares)107.8107.1
Weighted average shares outstanding - diluted (in shares)115.1114.0
Statements of Comprehensive Income  
Net income$ 722.0$ 817.8
Other comprehensive income (loss), net of tax:  
Unrealized gain on debt securities3.557.2
Gain on foreign currency translation0.20.0
Comprehensive income725.7875.0
Net product sales  
Revenues:  
Revenues1,761.31,668.0
Expenses:  
Cost of goods, collaboration and contract manufacturing240.4208.4
Collaboration revenue  
Revenues:  
Revenues1,266.81,378.1
Other revenue  
Revenues:  
Revenues116.9116.0
Cost of collaboration and contract manufacturing  
Expenses:  
Cost of goods, collaboration and contract manufacturing$ 193.4$ 249.1

REGN Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,602.0$ 2,730.0
Marketable securities7,917.58,114.8
Accounts receivable, net5,222.25,667.3
Inventories2,714.92,580.5
Prepaid expenses and other current assets414.9386.6
Total current assets18,871.519,479.2
Marketable securities6,978.85,396.5
Property, plant, and equipment, net4,225.54,146.4
Intangible assets, net1,058.71,038.6
Deferred tax assets2,764.92,575.4
Other noncurrent assets470.2444.1
Total assets34,369.633,080.2
Current liabilities:  
Accounts payable671.3606.6
Accrued expenses and other current liabilities2,392.92,357.9
Deferred revenue516.7458.9
Total current liabilities3,580.93,423.4
Long-term debt1,983.31,982.9
Finance lease liabilities720.0720.0
Deferred revenue185.8126.7
Other noncurrent liabilities908.5854.1
Total liabilities7,378.57,107.1
Stockholders' equity:  
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none0.00.0
Additional paid-in capital11,942.611,354.0
Retained earnings27,982.327,260.3
Accumulated other comprehensive loss(77.2)(80.9)
Treasury Stock, at cost; 25.8 shares in 2024 and 25.5 shares in 2023(12,856.7)(12,560.4)
Total stockholders' equity26,991.125,973.1
Total liabilities and stockholders' equity34,369.633,080.2
Class A Stock  
Stockholders' equity:  
Common stock0.00.0
Common Stock  
Stockholders' equity:  
Common stock$ 0.1$ 0.1
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
 CEO
 WEBSITEregeneron.com
 INDUSTRYBiotechnology
 EMPLOYEES12256

Regeneron Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Regeneron Pharmaceuticals Inc? What does REGN stand for in stocks?

REGN is the stock ticker symbol of Regeneron Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regeneron Pharmaceuticals Inc (REGN)?

As of Fri Jun 21 2024, market cap of Regeneron Pharmaceuticals Inc is 113.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers. The fair value of Regeneron Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Regeneron Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Regeneron Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether REGN is over valued or under valued. Whether Regeneron Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Regeneron Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REGN.

What is Regeneron Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, REGN's PE ratio (Price to Earnings) is 29.44 and Price to Sales (PS) ratio is 8.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regeneron Pharmaceuticals Inc's stock?

In the past 10 years, Regeneron Pharmaceuticals Inc has provided 0.142 (multiply by 100 for percentage) rate of return.